Search Prime Grants

R01AG092453

Project Grant

Overview

Grant Description
Cell-type-specific and spatial proteogenomics analysis of aberrant RNA splicing and misfolded proteins in Alzheimer's related tauopathies - Project summary / abstract

The molecular mechanisms of mis-folded protein accumulation in Alzheimer’s related tauopathies have been difficult to determine.

In response to RFA-AG-25-017, we have assembled a strong inter-institutional multi-investigator team with complementary expertise in spatial transcriptomics and proteogenomics platforms for the proposed project.

We hypothesize that vulnerable cell types in AD-impacted brain regions have detectable maladaptive gene expression profiles and epigenetic states that cause aberrant splicing and subsequent aberrant protein accumulation during AD/ADRD pathogenesis.

To test this hypothesis, we will comparatively study new tau-directed AD/ADRD mouse models and human AD/ADRD brain tissues.

We will use the “humanized” tau mouse models that replace the endogenous mouse MAPT gene with either a normal or pathogenic variant of the entire human MAPT gene (MAPT gene replacement, MAPT-GR), which express isoforms of human tau at physiologic levels and ratios.

In specific aim 1, we will generate single-cell spatial proteo-transcriptomics maps for molecular characterization of aberrant RNA splicing and abnormal protein products in specific cell types in the brain regions developing Alzheimer’s related tauopathy in mouse and human brains.

Specifically, we will combine multiple protein immunofluorescent staining with RNA MERFISH (multiplexed error-robust fluorescence in situ hybridization) on the same mouse brain sections to map aberrant mRNA splicing, spliceosome factors and Alzheimer’s hallmark proteins at different ages (3 months, 12 months; 18 months).

The mouse model studies will be complemented by the studies of misprocessed and aberrant RNAs and proteins in human postmortem brain tissues from early- and late-stage AD.

In specific aim 2, we will determine the impact of aberrant splicing on proteome dynamics and the development of Alzheimer’s related proteinopathies in mouse and human brains.

Considering that dysregulated RNA splicing disrupts proteome homeostasis in specific cell types and may cause the development of proteinopathies in AD/ADRD brains, we will generate a new METRS*; MAPT-GR mouse line by crossing the METRS* mouse with MAPT-GR mice to perform bio-orthogonal, non-canonical amino acid tagging (BONCAT) to incorporate the non-canonical amino acid azidonorleucine into newly synthesized proteins in four specific brain cell types: excitatory neurons, inhibitory neurons, microglia and astrocytes.

We will use a mass spectrometry-based proteomic Hyperion system to examine aberrantly spliced protein products and will use BONCAT to examine pulse labeled steady-state proteomics to demonstrate the effects of alternative/aberrant splicing on proteomics of specific cell types.

We will further test and validate the effects of alternative/aberrant splicing in human postmortem brain tissues from early- and late-stage AD subjects.

Together our proposed research will create cell-type-specific atlases of misprocessed and aberrant RNAs and proteins in mouse model and human brains, and will identify new molecular pathways and novel misprocessed protein interaction networks in Alzheimer’s related tauopathies.
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Place of Performance
Irvine, California 926970001 United States
Geographic Scope
Single Zip Code
Irvine University Of California was awarded Project Grant R01AG092453 worth $773,816 from National Institute on Aging in June 2025 with work to be completed primarily in Irvine California United States. The grant has a duration of 4 years 9 months and was awarded through assistance program 93.866 Aging Research. The Project Grant was awarded through grant opportunity Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumulation in Tauopathies (R01 Clinical Trial Not Allowed).

Status
(Ongoing)

Last Modified 6/5/25

Period of Performance
6/1/25
Start Date
3/31/30
End Date
4.0% Complete

Funding Split
$773.8K
Federal Obligation
$0.0
Non-Federal Obligation
$773.8K
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01AG092453

Additional Detail

Award ID FAIN
R01AG092453
SAI Number
R01AG092453-688899441
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
MJC5FCYQTPE6
Awardee CAGE
0VWL0
Performance District
CA-47
Senators
Dianne Feinstein
Alejandro Padilla
Modified: 6/5/25